AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Tyra Biosciences, Inc. Director's Dealing 2021

Sep 15, 2021

32575_dirs_2021-09-14_b12298bb-52ff-49be-ab7c-d14d32a03404.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Tyra Biosciences, Inc. (TYRA)
CIK: 0001863127
Period of Report: 2021-09-14

Reporting Person: Tada Hiroomi (Chief Medical Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	77922	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$0.61	2030-11-10	Common Stock (126246)		Direct
Stock Option (Right to Buy)	$2.25	2031-03-09	Common Stock (134937)		Direct

Footnotes

F1: Includes 77,922 shares subject to repurchase by us, which are subject to vesting.

F2: 25% of the shares subject to the option will vest on November 9, 2021, and 1/48th of the shares subject to the option vest monthly thereafter.

F3: 1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date.